OmniAb Inc
NASDAQ:OABI
Intrinsic Value
OmniAb, Inc. operates as a drug discovery company. [ Read More ]
The intrinsic value of one OABI stock under the Base Case scenario is 4.45 USD. Compared to the current market price of 4.57 USD, OmniAb Inc is Overvalued by 3%.
Valuation Backtest
OmniAb Inc
Run backtest to discover the historical profit from buying and selling OABI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
OmniAb Inc
Current Assets | 94.9m |
Cash & Short-Term Investments | 87m |
Receivables | 3.8m |
Other Current Assets | 4.1m |
Non-Current Assets | 280.3m |
PP&E | 38.1m |
Intangibles | 239.4m |
Other Non-Current Assets | 2.7m |
Current Liabilities | 23.1m |
Accounts Payable | 4.4m |
Accrued Liabilities | 9.3m |
Other Current Liabilities | 9.4m |
Non-Current Liabilities | 37.5m |
Other Non-Current Liabilities | 37.5m |
Earnings Waterfall
OmniAb Inc
Revenue
|
34.2m
USD
|
Operating Expenses
|
-103.6m
USD
|
Operating Income
|
-69.4m
USD
|
Other Expenses
|
18.8m
USD
|
Net Income
|
-50.6m
USD
|
Free Cash Flow Analysis
OmniAb Inc
OABI Profitability Score
Profitability Due Diligence
OmniAb Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
OmniAb Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
OABI Solvency Score
Solvency Due Diligence
OmniAb Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
OmniAb Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OABI Price Targets Summary
OmniAb Inc
According to Wall Street analysts, the average 1-year price target for OABI is 10.2 USD with a low forecast of 7.07 USD and a high forecast of 13.65 USD.
Ownership
OABI Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
OABI Price
OmniAb Inc
Average Annual Return | -50.43% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -71% |
Market Capitalization | 534m USD |
Shares Outstanding | 117 606 000 |
Percentage of Shares Shorted | 6.6% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 93 full-time employees. The company went IPO on 2020-10-09. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. Its OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach and OmniTaur features structural attributes of cow antibodies for complex targets. The firm's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic targets.
Contact
IPO
Employees
Officers
The intrinsic value of one OABI stock under the Base Case scenario is 4.45 USD.
Compared to the current market price of 4.57 USD, OmniAb Inc is Overvalued by 3%.